We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
States have an important role in ensuring food safety and healthy food practices.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
India is at a key inflexion point of not just ‘Heal in India’ through its vibrant medical value tourism, but also ‘Heal by India’, where our medical professionals can be used to serve not just our country but at the global level.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Subscribe To Our Newsletter & Stay Updated
